Axsome Therapeutics Joins the Global Narcolepsy Community in Raising Awareness on World Narcolepsy Day
In support of World Narcolepsy Day, Axsome is sponsoring several awareness events:
- On
Sept. 21 at6 p.m. Eastern Time , Axsome is sponsoring a virtual panel where an international group of experts will discuss narcolepsy around the world, organized by Wake Up Narcolepsy. Registration and details for the panel event can be found here. - On
Sept. 29-Oct. 1 , Axsome is a sponsor of and is attending “Thrive Together,” Narcolepsy Network’s 37th Annual Conference, a multi-day event to learn, engage, and connect with people with narcolepsy and their supporters, being held inDenver, Colo. More details about the conference can be found here.
Axsome is committed to developing innovative therapies that make an impact on the lives of people suffering from CNS disorders, including those with narcolepsy and other sleep disorders. As part of that mission, Axsome’s works closely with advocacy and other patient groups to support their efforts to provide a network and resources for patients and their families and to raise awareness of these conditions globally.
Narcolepsy is a serious and debilitating neurological condition that affects one out of 2000 people including an estimated 185,000 people in the
For more information about narcolepsy, World Narcolepsy Day, as well as additional resources for patients, please learn more about the following organizations and their affiliates:
- Wake Up Narcolepsy (https://www.wakeupnarcolepsy.org/): a nonprofit organization dedicated to driving narcolepsy awareness, education and research towards improved treatments and a cure.
- Narcolepsy Network (https://narcolepsynetwork.org/): is a national patient support organization dedicated to education, support and assistance, advocacy, and resources for people with narcolepsy.
Sleep Research Society (https://sleepresearchsociety.org/): an organization for scientific investigators who educate and research sleep and circadian science.Sleep Consortium (https://sleepconsortium.org/): a non-profit organization created to accelerate next generation research, disease understanding, and therapy development for those living with Central Disorders of Hypersomnolence (CDoH) and related diseases.National Sleep Foundation (https://www.thensf.org/): an independent nonprofit, dedicated to improving overall health and well-being by advancing sleep health.
About
Forward Looking Statements
Certain matters discussed in this press release are “forward-looking statements”. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the continued commercial success of our Sunosi® and Auvelity® products and the success of our efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the success, timing and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of our ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of our current product candidates; our ability to fund additional clinical trials to continue the advancement of our product candidates; the timing of and our ability to obtain and maintain
Axsome Contacts:
Investors:
Chief Operating Officer
Tel: 212-332-3243
Email: mjacobson@axsome.com
www.axsome.com
Media:
Director, Corporate Communications
Tel: 929-837-1065
Email: dopland@axsome.com
www.axsome.com
Source: Axsome Therapeutics, Inc.